On September 14, 2020 TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, reported that management will present virtually at the following upcoming industry conferences (Press release, TScan Therapeutics, SEP 14, 2020, View Source [SID1234565110]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 22nd Annual Global Investment Conference
David Southwell, Chief Executive Officer, will present a company overview on September 14, 2020, at 12:30 p.m. Eastern Time
CAR-TCR Digital Week
Gavin MacBeath, Ph.D., Chief Scientific Officer, will present "TScan, a Whole Genome, Unbiased Approach to Cancer Target Discovery" on September 14, 2020, at 1:45 p.m. Eastern Time
American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) COVID-19 Symposium
Dr. MacBeath will present the poster "Unbiased Genome-Wide Discovery Using TScan Reveals Shared Immunodominant CD8+ T Cell Epitopes in SARS-COV-2" in an oral session on September 16, 2020, at 5:00 p.m. Eastern Time
TCR-based Therapies Summit
Dr. MacBeath will lead the seminar "Expanding TCR Therapy by Identifying New Targets and TCRs from Patient TILs" on October 28, 2020, at 9:00 a.m. Eastern Time